Showing 5661-5670 of 9400 results for "".
- Two New Psoriasis Guidelines Address Comorbidities, Biologic Treatmenthttps://practicaldermatology.com/news/two-new-psoriasis-guidelines-address-comorbidities-biologic-treatment/2459901/The American Academy of Dermatology and the National Psoriasis Foundation have released two new guidelines outlining best practices for treating psoriasis with a focus on comorbidities and biologic treatment. Develo
- FDA Grants 510(k) Clearance to Laseroptek's PicoLOhttps://practicaldermatology.com/news/fda-grants-510k-clearance-to-laseropteks-picolo/2459903/Laseroptek’s PicoLO picosecond Nd:YAG laser is now U.S. Food and Drug Administration-cleared for marketing in dermatology and general and plastic surgery. According to the company, PicoLO generates high peak power and consistent picosecond pul
- Lutronic Genius RF Microneedling Platform Cleared by FDAhttps://practicaldermatology.com/news/lutronic-genius-rf-microneedling-platform-cleared-by-fda/2459905/Lutronic has received FDA clearance of the Lutronic Genius™ platform for radiofrequency microneedling. The company says the device transmits energy more precisely into the skin. The Lutronic Intelligent Care
- MedPharm Ltd. Expands Partnership with Palvella Therapeutics, Inc. for PC Treatmenthttps://practicaldermatology.com/news/medpharm-ltd-expands-partnership-with-palvella-therapeutics-inc-for-pc-treatment/2459906/MedPharm Ltd, is expanding its partnership with Palvella Therapeutics, Inc. MedPharm has employed its formulation expertise to support Palvella’s development of a novel,
- Combination Surgical Excision/Laser Treatment Improves Outcomes, Patient Satisfaction for CMNhttps://practicaldermatology.com/news/combination-surgical-excisionlaser-treatment-improves-outcomes-patient-satisfaction-for-cmn/2459908/Combining lasers with surgical excision produces cosmetically superior results compared to laser-only treatments for small to medium congenital melanocytic nevi (CMN), according to a new review. The
- New from BD: Prefillable Glass Syringe for Viscous Solutionshttps://practicaldermatology.com/news/new-from-bd-prefillable-glass-syringe-for-viscous-solutions/2459910/BD (Becton, Dickinson and Company) has presented BD Hylok,its new glass pre-fillable syringe for the administration of viscous solutions such as hyaluronic acid dermal fillers, at Pharmapack 2019. BD Hylokis also the first glass pre-fillab
- Study Finds Lack of Disclosure of Potential Conflicts of Interest in Dermatology Patient Advocacy Organizationshttps://practicaldermatology.com/news/study-finds-lack-of-disclosure-of-potential-conflicts-of-interest-in-dermatology-patient-advocacy-organizations/2459912/A recent study published in JAMA Dermatology was conducted to examine potential financial conflicts of interest and characterize disclosure practices among dermatology patient advocacy organizations. For this cross-sectional study of the largest dermatology patient ad
- Biologics May Reduce Plaque Buildup in Psoriasis Patients' Arterieshttps://practicaldermatology.com/news/biologics-may-reduce-plaque-buildup-in-psoriasis-patients-arteries/2459913/Treating psoriasis with biologic drugs can reduce the early plaque buildup that clogs arteries, restricts blood flow, and leads to heart attacks and stroke, according to a study funded by the Natio
- Vyome Secures $22M to Advance Dermatology Pipelinehttps://practicaldermatology.com/news/vyome-secures-22m-to-advance-dermatology-pipeline/2459918/Vyome Therapeutics Inc., a clinical-stage specialty pharmaceutical company developing novel medicines for treating skin diseases caused by resistant microbes, closed $22 million in financing. The company says it plans to primarily use the funds to advance its lead molecule, VB 19
- Menlo Therapeutics to Present Late-Breaking Oral Presentation at AAD Annual Meetinghttps://practicaldermatology.com/news/menlo-therapeutics-to-present-late-breaking-oral-presentation-at-aad-annual-meeting/2459917/Menlo Therapeutics Inc., a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus, has had its abstract accepted for oral presentation at the Late-Breaking Research Program during the 2019 Annual Meeting in Washington, DC. The ab